Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT04853758
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Registry
-
NCT04853758
-
- Other papers using this trial's data
- Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Unknown status
Technical summary
Registry record NCT04853758. Randomized; triple masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2024-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Acronym
- ANSWER-HF
- Condition
- Chagas Cardiomyopathy
- Intervention (Drug)
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Intervention (Drug)
- Enalapril
- Lead sponsor
- University of Sao Paulo General Hospital
- Collaborator
- InCor Heart Institute
Record details
- Record id
cardio:ct-nct04853758- Content hash
c1c780a87c17d03ef66d10f735d1e37abc0c9c1ce02d8dc26fe37c1f33f2e2bf